A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia

Related documents

• Structured experience shapes strategy learning and neural dynamics in the medial entorhinal cortex#652519
• Promiscuous Metal Site in Hepatitis B Virus X Protein Binds an Fe–S Cluster#652520
• A biochemical mechanism for Stu2/XMAP215-family microtubule polymerases#652521
• The metacognitive paradox of OCD: confidence is globally reduced but shows increased sensitivity to local evidence#652522
• A phenotypic paradigm for cerebral palsy genetics#652523